Literature DB >> 213489

Differences in activation of human and guinea pig complement by retroviruses.

R M Bartholomew, A F Esser.   

Abstract

C type murine leukemia viruses (retroviruses) have been shown previously to possess a receptor for human C1 that activated human but not guinea pig complement. In the present study we provide evidence that the viral receptor also binds guinea pig C1 but that such binding does not lead to activation. However, incorporation of human C1s into guinea pig C1 to form a C1 hybrid results in activation of that hybrid and in viral lysis. In contrast, incorporation of guinea pig C1s into human C1 abolishes activation by the virus. These results demonstrate that C1s governs the activation of C1 of the viral receptor.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 213489

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Antibody-independent activation of the classical pathway of complement by Epstein-Barr virus.

Authors:  H Martin; I McConnell; B Gorick; N C Hughes-Jones
Journal:  Clin Exp Immunol       Date:  1987-03       Impact factor: 4.330

2.  Requirement for an additional serum factor essential for the antibody-independent activation of the classical complement sequence by Gram-negative bacteria.

Authors:  F Clas; M Loos
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

Review 3.  The complement system: its importance in the host response to viral infection.

Authors:  R L Hirsch
Journal:  Microbiol Rev       Date:  1982-03

4.  The relationship between the binding ability and the rate of activation of the complement component C1.

Authors:  E J Folkerd; B Gardner; N C Hughes-Jones
Journal:  Immunology       Date:  1980-09       Impact factor: 7.397

5.  The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent.

Authors:  N J DePolo; C E Harkleroad; M Bodner; A T Watt; C G Anderson; J S Greengard; K K Murthy; T W Dubensky; D J Jolly
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

6.  Antibody-independent binding of the first component of complement (C1) and its subcomponent C1q to the S and R forms of Salmonella minnesota.

Authors:  F Clas; M Loos
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

7.  Killing of the S and Re forms of Salmonella minnesota via the classical pathway of complement activation in guinea-pig and human sera.

Authors:  F Clas; M Loos
Journal:  Immunology       Date:  1980-08       Impact factor: 7.397

8.  Evaluation of the Galalpha1-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses.

Authors:  R M Welsh; C L O'Donnell; D J Reed; R P Rother
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

9.  Complement-Mediated Neutralisation Identified in Ebola Virus Disease Survivor Plasma: Implications for Protection and Pathogenesis.

Authors:  Jack Mellors; Tom Tipton; Sarah Katharina Fehling; Joseph Akoi Bore; Fara Raymond Koundouno; Yper Hall; Jacob Hudson; Frances Alexander; Stephanie Longet; Stephen Taylor; Andrew Gorringe; N'Faly Magassouba; Mandy Kader Konde; Julian Hiscox; Thomas Strecker; Miles Carroll
Journal:  Front Immunol       Date:  2022-04-12       Impact factor: 8.786

Review 10.  The immunobiology of the feline leukemia virus.

Authors:  J L Rojko; R G Olsen
Journal:  Vet Immunol Immunopathol       Date:  1984-05       Impact factor: 2.046

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.